Scientists test novel HIV vaccine strategy in first human trial
NCT ID NCT05781542
Summary
This early-stage study tested the safety and immune response of a new HIV vaccine approach in 46 healthy adults without HIV. Participants received synthetic DNA injections, some with an additional protein boost, to see if they could trigger specific immune responses against HIV. The main goal was to check for side effects and see if the vaccine stimulated the desired immune cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Alabama CRS (Site ID: 31788)
Birmingham, Alabama, 35294, United States
-
Bridge HIV CRS
San Francisco, California, 94102, United States
-
Brigham and Women's Hospital Vaccine CRS [30007]
Boston, Massachusetts, 02115, United States
-
CAPRISA eThekwini CRS
Durban, KwaZulu-Natal, 4013, South Africa
-
Durban Adult HIV CRS
Durban, KwaZulu-Natal, South Africa
-
Groote Schuur HIV CRS (Site ID: 31708)
Cape Town, Western Cape, 7925, South Africa
-
San Francisco Vaccine and Prevention CRS
San Francisco, California, 94102, United States
-
Soweto HVTN CRS
Johannesburg, Gauteng, South Africa
Conditions
Explore the condition pages connected to this study.